文献速递心力衰竭与心肌病

肥胖相关HFpEF中的炎症:STEP-HFpEF项目解读

Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program.
PubMed 文献 · J Am Coll Cardiol · 2024-08-30

Semaglutide 2.4 mg每周一次在基线各CRP分层中均一致改善心衰症状、体力限制、6分钟步行距离及体重,并降低CRP,且CRP降低与体重减轻程度无关。

要点

  • 肥胖相关HFpEF中炎症(CRP≥2 mg/L)患病率高达71%。
  • Semaglutide改善心衰症状、体力限制及体重,不受基线CRP水平影响。
  • Semaglutide降低CRP,与基线CRP及体重减轻幅度无关。

核心结论

  • 炎症在肥胖相关HFpEF中高度流行,Semaglutide在各基线CRP分层中一致改善心衰相关症状、体力限制、运动功能及体重,并降低炎症,且CRP降低与基线CRP或体重减轻幅度无关。

主要发现

  • 71%患者有炎症证据(CRP≥2 mg/L)。
  • 基线炎症水平较高者更年轻、女性比例更高、BMI更高、KCCQ-CSS更差、6MWD更短。
  • Semaglutide对比安慰剂降低心衰相关症状和体力限制、降低体重、改善6MWD和分层复合终点,在各基线CRP类别中一致(交互P均不显著)。
  • Semaglutide降低CRP程度大于安慰剂,不受基线CRP水平影响(交互P=0.32)。
  • 52周CRP变化与体重减轻幅度无关(交互P=0.91)。

关键数值与推荐

  • 炎症定义为基线CRP≥2 mg/L,71%患者符合。
  • CRP分层:<2、≥2至<10、≥10 mg/L。
  • 主要终点为52周KCCQ-CSS和体重变化。
  • 额外终点包括6MWD变化、分层复合终点(死亡、心衰事件、KCCQ-CSS与6MWD变化差异)及CRP水平。

临床怎么用

  • 对肥胖相关HFpEF患者应关注炎症状态(CRP≥2 mg/L)。
  • Semaglutide 2.4 mg每周一次可考虑用于改善症状、体力限制、运动功能及体重,不受基线CRP影响。
  • Semaglutide降低CRP独立于基线CRP和体重减轻幅度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inflammation is thought to be an important mechanism for the development and progression of obesity-related heart failure with preserved ejection fraction (HFpEF). In the STEP-HFpEF Program, once-weekly 2.4 mg semaglutide improved heart failure-related symptoms, physical limitations, and exercise function, reduced the levels of C-reactive protein (CRP), a biomarker of inflammation, and reduced body weight in participants with obesity-related HFpEF. However, neither the prevalence nor the clinical characteristics of patients who have various magnitudes of inflammation in the context of obesity-related HFpEF have been well described. Furthermore, whether the beneficial effects of semaglutide on the various HF efficacy endpoints in the STEP-HFpEF Program are modified by the baseline levels of inflammation has not been fully established. Finally, the relationship between weight reduction and changes in CRP across the STEP-HFpEF Program have not been fully defined. OBJECTIVES: This study sought to: 1) evaluate baseline characteristics and clinical features of patients with obesity-related HFpEF that have various levels of inflammation in the STEP-HFpEF Program; 2) determine if the effects of weekly semaglutide 2.4 mg vs placebo across all key outcomes are influenced by baseline levels of inflammation assessed by CRP levels; and 3) determine the relationship between change in CRP and weight loss in the STEP-HFpEF Program. METHODS: This was a secondary analysis of pooled data from 2 international, double-blind, placebo-controlled, randomized trials (STEP-HFpEF and STEP-HFpEF DM). The outcomes were change in the dual primary endpoints (health status [measured by the Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS)] and body weight) from baseline to 52 weeks according to baseline CRP levels. Additional efficacy endpoints included change in 6-minute walk distance (6MWD), a hierarchical composite endpoint that included death, heart failure events, and differences in the change in the KCCQ-CSS and 6MWD, and levels of CRP in semaglutide- vs placebo-treated patients. Patients were stratified into 3 categories based on baseline CRP levels (<2, ≥2 to <10, and ≥10 mg/L). RESULTS: In total, 1,145 patients were randomized, of which 71% of patients had evidence of inflammation (CRP ≥2 mg/L). At baseline, those with higher levels of inflammation were younger, were more likely to be female, and had higher body mass index, worse health status (KCCQ-CSS), and shorter 6MWD. Semaglutide vs placebo led to reductions in HF-related symptoms and physical limitations as well as body weight, and to improvements in 6MWD and the hierarchical composite endpoint that were consistent across baseline CRP categories (all P interaction nonsignificant). Semaglutide also reduced CRP to a greater extent than placebo regardless of baseline CRP levels (P interaction = 0.32). Change in CRP from baseline to 52 weeks was similar regardless of the magnitude of weight loss (P interaction = 0.91). CONCLUSIONS: Inflammation is highly prevalent in obesity-related HFpEF. Semaglutide consistently improved HF-related symptoms, physical limitations, and exercise function, and reduced body weight across the categories of baseline CRP. Semaglutide also reduced inflammation, regardless of either baseline CRP or magnitude of weight loss during the trials. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [STEP-HFpEF; NCT04788511]; Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes [STEP HFpEF DM; NCT04916470]).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Verma S, Petrie MC, Borlaug BA, et al. Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program. J Am Coll Cardiol. 2024. PMID: 39217564. doi:10.1016/j.jacc.2024.08.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。